Prognostic Significance of Targetable Angiogenic and Growth Factors in Patients Undergoing Resection for Gastric and Gastroesophageal Junction Cancers

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

(2013) Tom Waddell et al.   LANCET ONCOLOGY

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

(2013) Florian Lordick et al.   LANCET ONCOLOGY

Comparison of a Lymph Node Ratio–Based Staging System With the 7th AJCC System for Gastric Cancer

(2012) Jiping Wang et al.   ANNALS OF SURGERY

Targeting the HGF/Met signaling pathway in cancer therapy

(2012) Fabiola Cecchi et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets

(2012) Niantao Deng et al.   GUT

Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial

(2012) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Genomic Dysregulation in gastric tumors

(2012) Yelena Y. Janjigian et al.   JOURNAL OF SURGICAL ONCOLOGY

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

(2011) Atsushi Ohtsu et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

(2010) Yung-Jue Bang et al.   LANCET

Breast cancer assessment tools and optimizing adjuvant therapy

(2010) Catherine Oakman et al.   Nature Reviews Clinical Oncology